Bank of America Securities Reaffirms Buy Rating on Sino Biopharm Following Positive Progress on Two Drug Candidates
Stock News
Feb 12
Bank of America Securities has issued a research report highlighting that Sino Biopharm (01177) has recently completed patient enrollment for the Phase 3 clinical trials of its two drug candidates, TQB2102 and LM302. Notably, LM302 is the first CLDN18.2 antibody-drug conjugate globally to complete patient enrollment for a Phase 3 registrational clinical study, potentially offering a new treatment option for patients. The firm maintains a target price of HK$8.6 and reiterates its "Buy" rating on the stock.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.